Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: NHLRC2 expression is increased in idiopathic pulmonary fibrosis

Fig. 3

Relative NHLRC2 protein expression in idiopathic pulmonary fibrosis (IPF) and control lungs. The area of positive immunohistochemical NHLRC2 expression was quantified with Visiopharm digital pathology image analysis software in relation to the whole tissue section area. A NHLRC2 expression was higher in IPF patients at the stable phase of the disease (n = 47) compared to controls (n = 10) (p < 0.001). B NHLRC2 expression was higher in IPF patients not experiencing acute exacerbation (AE) during follow-up (IPF 1, n = 28), IPF patients experiencing AE during follow-up (IPF 2, n = 19), and IPF patients experiencing AE at the time of biopsy (AE-IPF, n = 3) compared to controls (n = 10) (p = 0.022, p = 0.005, p = 0.007, respectively). There was a trend of AE-IPF patients (n = 3) having a higher NHLRC2 expression compared to IPF patients at the stable phase of the disease not experiencing AE during follow-up (IPF 1, n = 28), and patients experiencing AE during follow-up (IPF 2, n = 19) (p = 0.473 and p = 1.000, respectively). C There was a trend of current and ex-smokers (n = 26) having higher NHLRC2 expression compared to non-smokers (n = 17) (p = 0.060) at the stable phase of the disease. D–F NHLRC2 expression did not differ between males (n = 34) and females (n = 13) (p = 0.549), in patients IPF patients with high percent predicted forced vital capacity (FVC%) (n = 21) and low FVC% (n = 20) (p = 0.190) or in patients with high percent predicted diffusing capacity for carbon monoxide (DLCO%) (n = 21) and low DLCO% (n = 19) (p = 0.247)

Back to article page